| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3949d89b3d66307e15c5548e1aa82b61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_938ddfffc83915ad01a09773b7773ee6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9c7bc472e1f53bf8909900d3e34b8aa6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f83060621b8a10541f8f03e322511f65 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-115 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7016
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-733
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-047 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
| filingDate |
2013-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c50d5fdb8ebd677d4a6984dd4c4a9d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ce6db467ddecc66f912b1ceb653ec3c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b8a1c1cca23e250f5d15071a3ca0bb2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d673174e562d2f254b4701447ac638ca |
| publicationDate |
2015-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015202192-A1 |
| titleOfInvention |
Pharmaceutical composition for treating gastro-oesophageal reflux disease |
| abstract |
The invention relates to medicine and pharmacology, more particularly to drugs, and even more particularly to pharmaceutical compositions for treating gastroesophageal reflux disease (GERD). The pharmaceutical composition for treating GERD contains at least one proton pump inhibitor (PPI) and at least one prebiotic. Also claimed is a method for treating gastroesophageal reflux disease in which it is not necessary to eradicate the presence of H. pylori in order to prevent the risks associated with the translocation of said bacteria from the antrum to the body of the stomach. The composition provides for prevention of the translocation of H. pylori by means of the colonization of the antrum by lactobacilli and the concurrent inhibition of H. pylori during PPI therapy. This makes it possible to dispense with the need to detect the bacteria and carry out a course of eradication therapy. The safety of long-term PPI therapy is increased. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11123394-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2768108-C2 |
| priorityDate |
2012-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |